45 results on '"De Meyer, A."'
Search Results
2. Diagnosis of thrombotic thrombocytopenic purpura: easy-to-use fiber optic surface plasmon resonance immunoassays for automated ADAMTS-13 antigen and conformation evaluation
3. Open ADAMTS-13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura
4. Toward gene therapy for congenital thrombotic thrombocytopenic purpura
5. In vitro characterization of a novel Arg102 mutation in the ADAMTS13 metalloprotease domain
6. ADAMTS13 inhibition to treat acquired von Willebrand syndrome during mechanical circulatory support device implantation
7. Thrombus formation during ECMO: Insights from a detailed histological analysis of thrombus composition
8. Basic science research opportunities in thrombosis and hemostasis: Communication from the SSC of the ISTH
9. Immunogenic hotspots in the spacer domain of ADAMTS13 in immune‐mediated thrombotic thrombocytopenic purpura
10. Von Willebrand factor and ADAMTS13 impact on the outcome of Staphylococcus aureus sepsis
11. Diagnosis of thrombotic thrombocytopenic purpura: Easy-to-use fiber-optic surface plasmon resonance immunoassays for automated ADAMTS13 antigen and conformation evaluation
12. von Willebrand factor in experimental malaria‐associated acute respiratory distress syndrome
13. Enhanced activity of an ADAMTS‐13 variant (R568K/F592Y/R660K/Y661F/Y665F) against platelet agglutination in vitro and in a murine model of acute ischemic stroke
14. High and long‐term von Willebrand factor expression after Sleeping Beauty transposon‐mediated gene therapy in a mouse model of severe von Willebrand disease
15. An open conformation of ADAMTS‐13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura
16. Open ADAMTS-13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura
17. Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice
18. Linker regions and flexibility around the metalloprotease domain account for conformational activation of ADAMTS‐13
19. The novel ADAMTS13‐p.D187H mutation impairs ADAMTS13 activity and secretion and contributes to thrombotic thrombocytopenic purpura in mice
20. In vitro characterization of a novel Arg102 mutation in the ADAMTS13 metalloprotease domain
21. Animal models for thrombotic thrombocytopenic purpura
22. Neutrophil extracellular traps promote deep vein thrombosis in mice
23. The distal carboxyterminal domains of murine ADAMTS13 influence proteolysis of platelet‐decorated VWF strings in vivo
24. Determination of anti‐ADAMTS‐13 autoantibody titers in ELISA: Influence of ADAMTS‐13 presentation and autoantibody detection
25. Recombinant ADAMTS13 as an effective therapy for acquired thrombotic thrombocytopenic purpura in rats: OR151
26. Endogenous plasmin levels control the development of acute episodes of thrombotic thrombocytopenic purpura in mice: OR153
27. Long-term gene therapy for thrombotic thrombocytopenic purpura using the ‘Sleeping Beauty’ transposon system: OR155
28. Long-term expression of von willebrand factor VIA sleeping beauty sandwich transposon-mediated gene therapy: OR087
29. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS‐13)
30. Anti‐ADAMTS13 autoantibodies in immune‐mediated thrombotic thrombocytopenic purpura do not hamper ELISA‐based quantification of ADAMTS13 antigen
31. In vitrocharacterization of a novel Arg102 mutation in the ADAMTS13 metalloprotease domain
32. A new heterozygous mutation in the metalloprotease domain of ADAMTS13 in a patient with thrombotic thrombocytopenic purpura: PB 2.73–2
33. The role of platelet von Willebrand factor in mice: OC 65.4
34. The newly identified platelet receptor DCBLD2 is involved in platelet activation and thrombus formation: OC 60.6
35. ADAMTS13 meets von Willebrand factor strings: a single molecule approach: OC 15.1
36. ADAMTS13inhibition to treat acquired von Willebrand syndrome during mechanical circulatory support device implantation
37. In vivo von Willebrand factor size heterogeneity in spite of the clinical deficiency of ADAMTS-13
38. von Willebrand factor increases in experimental cerebral malaria but is not essential for late‐stage pathogenesis in mice
39. Deficiency of von willebrand factor protects mice from ischemic stroke: OC-WE-040
40. RESTORATION OF VON WILLEBRAND FACTOR FUNCTION IN A MURINE MODEL OF SEVERE VON WILLEBRAND DISEASE AFTER LIVER SPECIFIC GENE TRANSFER
41. In vivo von Willebrand factor size heterogeneity in spite of the clinical deficiency of ADAMTS‐13
42. Enhanced activity of an ADAMTS‐13 variant (R568K/F592Y/R660K/Y661F/Y665F) against platelet agglutination in vitroand in a murine model of acute ischemic stroke
43. High and long‐term von Willebrand factor expression after Sleeping Beautytransposon‐mediated gene therapy in a mouse model of severe von Willebrand disease
44. RESTORATION OF VON WILLEBRAND FACTOR FUNCTION IN A MURINE MODEL OF SEVERE VON WILLEBRAND DISEASE AFTER LIVER SPECIFIC GENE TRANSFER
45. In vivovon Willebrand factor size heterogeneity in spite of the clinical deficiency of ADAMTS‐13
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.